SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 2,700 Shares

Key Points

• Insider Philippe Menu sold 2,700 shares on April 6 at an average price of $4.85 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vesting, leaving him with 283,852 shares (a 0.94% reduction).
• Multiple executives (including the CEO, President, CFO and CTO) executed pre-arranged Rule 10b5-1 sales across April 6–7 totaling roughly 25,000 shares for about $120k, with filings characterizing these as routine, plan-driven sales.
• SOPHiA GENETICS remains unprofitable (negative EPS and margins) with a market cap of about $333M and the stock trading near $4.86, while analysts’ average price target is $7.00 amid mixed ratings.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 2,700 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $4.85, for a total value of $13,095.00. Following the sale, the insider directly owned 283,852 shares in the company, valued at $1,376,682.20. This trade represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,688.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.04 during midday trading on Wednesday, hitting $4.86. 71,758 shares of the company traded hands, compared to its average volume of 188,492. The company's 50-day moving average is $4.78 and its 200 day moving average is $4.68. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. SOPHiA GENETICS SA has a 52 week low of $2.58 and a 52 week high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. On average, research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC raised its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC purchased a new position in SOPHiA GENETICS during the third quarter valued at $6,708,000. Finally, Savvy Advisors Inc. purchased a new position in SOPHiA GENETICS during the third quarter valued at $48,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, BTIG Research reiterated a "buy" rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.